JSPR · Jasper Therapeutics, Inc. · Executive Compensation
$0.51
+0.03 (+6.70%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, based on the Company's current operating plan, and along with the Company's history of operating losses, and given the potential risk of having to repurchase the Non-Voting Convertible Preferred Stock if the Company is unable to obtain stockholder approval to convert it to Common Stock within 12 months, the Company's current cash and cash equivalents may not be sufficient to fund the Company's ongoing operations for a period of at least twelve months from the issuance date of these condensed consolidated financial statements. Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$15.89M
Shares
33.27M
Volume · Oct 20
325.93K
Avg daily vol (3M)
564.32K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | Former Chief Executive Officer and President | $2,494,099 |
| Edwin Tucker | Former Chief Medical Officer | $1,537,032 |
| Jeet Mahal | Chief Executive Officer and President; Former Chief Operating Officer | $1,289,599 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | $1,283,474 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | Former Chief Executive Officer and President | $3,215,003 |
| Edwin Tucker | Former Chief Medical Officer | $1,400,620 |
| Jeet Mahal | Chief Executive Officer and President; Former Chief Operating Officer | $1,278,131 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | $1,270,940 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | President and Chief Executive Officer | $3,369,990 |
| Jeet Mahal | Chief Operating Officer | $1,184,707 |
| Edwin Tucker | Chief Medical Officer | $977,726 |
| Herb Cross | Chief Financial Officer and Corporate Secretary | $643,122 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ronald Martell | President and Chief Executive Officer | $5,640,190 |
| Jeet Mahal | Chief Operating Officer | $1,107,520 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| William Lis | Former Executive Chairman, Chief Executive Officer and President | $679,289 |
| Kevin N. Heller | Executive Vice President, Research and Development | $617,987 |
| Jeet Mahal | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | $461,121 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| William Lis | Former Executive Chairman, Chief Executive Officer and President | $1,571,061 |
| Kevin N. Heller | Executive Vice President, Research and Development | $1,212,858 |
| Jeet Mahal | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | $719,959 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Rick Ruiz | interim Principal Accounting Officer | Appointed | 2026-09-28 |
| Matthew Ros | interim Corporate Secretary | Appointed | 2026-09-28 |
| Jeet Mahal | interim Principal Financial Officer | Appointed | 2026-09-28 |
| Herb Cross | Corporate Secretary | Resigned | 2026-09-28 |
| Herb Cross | Principal Accounting Officer | Resigned | 2026-09-28 |
| Herb Cross | Chief Financial Officer | Resigned | 2026-09-28 |
| Patrick Crutcher | Class I director | Appointed | 2026-07-17 |
| Matthew Ros | Chief Operating Officer | Appointed | 2026-07-17 |
| Scott Brun, M.D. | Director | Resigned | 2026-07-17 |
| Vishal Kapoor | Director | Resigned | 2026-07-17 |
| Christian Nolet | Board and the committees of the Board on which he serves | Resigned | 2026-05-21 |
| Thomas G. Wiggans | Executive Chair | Appointed | 2026-01-07 |
| Jeet Mahal | Chief Executive Officer and President | Appointed | 2026-01-07 |
| Jeet Mahal | Class III director | Appointed | 2026-01-07 |
| Ron Martell | Board | Resigned | 2026-01-07 |
| Ron Martell | Chief Executive Officer and President | Terminated | 2026-01-07 |
| Dr. Edwin Tucker, M.D. | Chief Medical Officer | Terminated | 2025-07-09 |
| Svetlana Lucas, Ph.D. | Class III director | Appointed | 2024-06-20 |
| Anna French, D.Phil. | Board of Directors | Resigned | 2024-06-20 |
| Christian W. Nolet | Class III director | Appointed | 2024-06-12 |
| Ronald Martell | Class III director | Appointed | 2024-06-12 |
| William Lis | Chairperson of the Board | Resigned | 2023-11-01 |
| William Lis | Board | Resigned | 2023-11-01 |
| Thomas G. Wiggans | Chairperson of the Board | Appointed | 2023-11-01 |
| Thomas G. Wiggans | Class II director | Appointed | 2023-11-01 |
Leadership
- Jeet Mahal CEO, COO, Board Member
- Ronald Martell CEO, Board Member
- William Lis CEO
- Howard Hoffen Chairman
- Thomas G. Wiggans Chairman, Board Member
- Matthew Ros COO, General Counsel
- Rick Ruiz Chief Accounting Officer
- Anna French, D. Phil. Board Member
- Christian W. Nolet Board Member
- Judith Shizuru, M.D., Ph.D. Board Member
- Kurt von Emster Board Member
- Patrick Crutcher Board Member
- Scott Brun, M.D. Board Member
- Svetlana Lucas, Ph.D. Board Member
- Vishal Kapoor Board Member